{ "items": [ "\n\n
Dritsaki M. et al, (2018), Pharmacoeconomics, 36, 253 - 257
\n \n \n \n\n \n
\n \n \nPng ME. et al, (2018), Wellcome open research, 3, 156 - 156
\n \n \n \n\n \n
\n \n \nBraithwaite T. et al, (2018), Health Policy Plan, 33, 70 - 84
\n \n \n \n\n \n
\n \n \nLokuge K. et al, (2018), British Journal of Surgery, 105, 26 - 36
\n \n \n \n\n \n
\n \n \nMostafa SA. et al, (2018), Diabet Med, 35, 72 - 77
\n \n \n \n\n \n
\n \n \nVergunst F. et al, (2017), Health Qual Life Outcomes, 15
\n \n \n \n\n \n
\n \n \nMorton RL. et al, (2017), Kidney International Reports
\n \n \n \n\n \n
\n \n \nNanchahal J. et al, (2017), Wellcome Open Research
\n \n \n \n\n \n
\n \n \nWolstenholme JL. et al, (2017)
\n \n \n \n\n \n
\n \n \nFusco R. et al, (2017), VALUE IN HEALTH, 20, A445 - A446
\n \n \n \n\n \n
\n \n \nWasan H. et al, (2017), Annals of Oncology, 28, x43 - x44
\n \n \n \n\n \n
\n \n \nMurphy JFE. et al, (2017), BMJ Open
\n \n \n \n\n \n
\n \n \nShepperd S. et al, (2017), Trials, 18, 491 - 491
\n \n \n \n\n \n
\n \n \nGRAY A., (2017), Health and quality of life outcomes, 15, 185 - 185
\n \n \n \n\n \n
\n \n \nColeman RL. et al, (2017), DIABETOLOGIA, 60, S522 - S522
\n \n \n \n\n \n
\n \n \nWasan H. et al, (2017), ANNALS OF ONCOLOGY, 28
\n \n \n \n\n \n
\n \n \nGray AM. et al, (2017), ANNALS OF ONCOLOGY, 28
\n \n \n \n\n \n
\n \n \nGray AM. et al, (2017), DIABETOLOGIA, 60, S357 - S357
\n \n \n \n\n \n
\n \n \nBowman L. et al, (2017), New England Journal of Medicine
\n \n \n \n\n \n
\n \n \nEibich UPR. et al, (2017), Diabetes Therapy
\n \n \n \n\n \n
\n \n \n